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Background: To investigate the antidiabetic effects of hydrolyzed ginseng extract (HGE) for Korean
participants in an 8-wk, randomized, double-blinded, placebo-controlled clinical trial.
Methods: Impaired fasting glucose participants [fasting plasma glucose (FPG)  5.6mM or < 6.9mM]
who had not been diagnosed with any disease and met the inclusion criteria were recruited for this
study. The 23 participants were randomly divided into either the HGE (n ¼ 12, 960 mg/d) or placebo
(n ¼ 11) group. Outcomes included measurements of efﬁcacy (FPG, postprandial glucose, fasting plasma
insulin, postprandial insulin, homeostatic model assessment-insulin resistance, and homeostatic model
assessment-b) and safety (adverse events, laboratory tests, electrocardiogram, and vital signs).
Results: After 8 wk of HGE supplementation, FPG and postprandial glucose were signiﬁcantly decreased
in the HGE group compared to the placebo group. No clinically signiﬁcant changes in any safety
parameter were observed. Our study revealed that HGE is a potent antidiabetic agent that does not
produce noticeable adverse effects.
Conclusion: HGE supplementation may be effective for treating impaired fasting glucose individuals.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
There is much concern about the dramatic increase in the
population of type 2 diabetes patients. Both the recent prevalence
rate and the estimated increase in incidence have become public
health problems and create a serious burden on society. In order to
identify an individual at increased risk of developing type 2 dia-
betes, the concept of impaired fasting glucose (IFG) has been
introduced by the American Diabetes Association [1]. Individuals
with IFG have fasting plasma glucose levels between 5.6 mmol/L
and 6.9 mmol/L [2]. In addition to being more likely to developerms of the Creative Commons At
ribution, and reproduction in any
e Korean Society of Ginseng, Publdiabetes in the near future, these people are at greater risk for
cardiovascular disease [3,4]. Therefore, effective approaches to
control blood glucose levels are urgently needed. Previous large-
scale studies have demonstrated that lifestyle intervention is the
best way to achieve this goal [5e7]. Pharmacotherapy is also used
to manage individuals with IFG. Paradoxically, medications used to
control blood glucose often cause metabolic side effects such as
weight gain [8,9]. Thus, the development of alternative therapies is
of paramount importance, and in this context, herbal extracts are
among the most promising source of new treatments for the pre-
vention of diabetes.tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
medium, provided the original work is properly cited.
ished by Elsevier. All rights reserved.
Table 1
Composition of test products provided/d
Placebo supplement Hydrolyzed ginseng extract supplement
Component Content (%) Component Content (%)
Powdered rice 10 Fermented ginseng extract 30
Pumpkin seeds oil 65.84 Pumpkin seeds oil 55.4
Reﬁned palm oil 15.44 Reﬁned palm oil 9.0
Yellow wax 7.72 Yellow wax 4.6
Sorbic acid 1 Sorbic acid 1
Total 100 Total 100
J Ginseng Res 2014;38:239e243240Ginseng (Panax ginseng Meyer) has been used as traditional
medicine in the treatment of metabolic diseases, cancer, cardio-
vascular diseases, and other diseases in a number of Asian countries
[10e12]. The bioactive constituents of ginseng include various sa-
ponins (ginsenosides) and nonsaponins, and the pharmacological
activities of ginseng are mainly attributed to ginsenosides [13,14].
To date, 80 ginsenosides have been identiﬁed in ginseng. These
ginsenosides are further biotransformed by intestinal bacteria,
which increase intestinal absorption and bioactivity and diminish
the toxicity of the metabolite compared to its parent compound
[15,16]. In this regard, fermentation using microorganisms or
treatment with an appropriate enzyme for the production of more
effective compounds has been extensively studied.
In previous studies, pectinase was used for the biotransforma-
tion of ginsenosides in ginseng extract, and this process increased
the level of bioactive compounds, including compound K (also
known as IH-901), resulting in improved pharmacological func-
tions [17,18]. Although the antidiabetic activities of ginseng have
been well documented in animal [19] and human [20] studies, the
improved effects of hydrolyzed ginseng on diabetic patients are not
clear. Therefore, in this study, we investigated whether hydrolyzed
ginseng extract (HGE) could be effective in reducing the risk of type
2 diabetes in individuals with IFG.
2. Materials and methods
2.1. Study design
This study was an 8-wk, randomized, double-blinded, placebo-
controlled clinical trial. The randomization scheme was generated
by a computerized procedure. Neither the investigators nor the
participants knew the randomization code until the trial was
completed and database locked. Participants who responded and
met the entry criteria during a telephone screening interview were
scheduled for a baseline visit. Participants were scheduled for a
screening visit, during which the informed consent was reviewed
and signed. At 0 wk and 8 wk, a 75-g oral glucose tolerance test
(OGTT) was performed after an overnight fast. A catheter was
inserted intoaveinandbloodsampleswereobtainedprior to (0min)
and after (15min, 30min, 60min, 90min, and120min) consuming a
75-g glucose drink. During the 8-wk intervention period, partici-
pants were asked to continue their usual diets and to not take any
other functional foods or dietary supplements. Participants were
also asked to report for the assessment of any adverse events or any
changes in lifestyle andeatingpatterns and toassesspill compliance.
2.2. Participants
The study participants were recruited from the Clinical Trial
Center for Functional Foods at Chonbuk National University Hos-
pital, Jeonbuk, Republic of Korea during 2009. IFG participants
[fasting plasma glucose (FPG) 5.6mM and< 6.9mM] who had not
been diagnosed with any disease and met the inclusion criteria
were recruited for this study. Exclusion criteria for the study were:
(1) abnormal lipid proﬁle values; (2) acute/chronic inﬂammation;
(3) treatment with corticosteroids within the past 4 wk; (4) car-
diovascular disease, such as arrhythmia, heart failure, myocardial
infarction, or a pacemaker; (5) allergic or hypersensitivity to any of
the ingredients in the test products; (6) history of a disease that
could interfere with the test products or impede their absorption,
such as gastrointestinal disease (Crohn’s Disease) or gastrointes-
tinal surgery; (7) participation in any other clinical trials within the
past 2 mo; (8) renal disease, such as acute/chronic renal failure or
nephrotic syndrome; (9) abnormal hepatic function; (10) treatment
by hypolipidemic drug therapy within the past 3 mo; (11)treatment by antipsychotic drug therapy within the past 2 mo; (12)
a laboratory test, medical, or psychological conditions deemed by
the investigators to interfere with successful participation in the
study; (13) history of alcohol or substance abuse; or (14) pregnancy
or breast feeding. All participants gave written informed consent
prior to beginning the study. The protocol was approved by the
Functional Foods Institutional Review Board (FFIRB) of Chonbuk
National University Hospital (FFIRB number: 2009-02-001). The
protocol was registered in www.clinicaltrials.gov (NCT01854164).
2.3. Test supplement
HGEwas obtained from ILHWACo. Ltd, (Guri, Republic of Korea),
as described previously, with slight modiﬁcations [17]. The HGE
contained 7.54 mg/g of Rg1, 1.87 mg/g of Re, 5.42 mg/g of Rb1,
0.29 mg/g of Rc, 0.36 mg/g of Rb2, and 0.70 mg/g of Rd. The com-
pound K content in the HGE was 6.3 mg/g. It was administered as a
capsule (480 mg/cap and 960 mg/d) composed of 30% HGE and 70%
diluting agent (pumpkin seed oil, reﬁned palm oil, yellow wax, and
sorbic acid). The placebo capsules were composed primarily of
powdered rice and pumpkin seed oil and were matched with re-
gard to energy content, ﬂavor, appearance, and dosage (Table 1).
All participants were instructed to take two capsules/d (one
capsule each after breakfast and dinner). HGE and placebo capsules
were packaged indistinguishably and labeled with the participant’s
number. Participants were instructed to bring all remaining sup-
plements at each visit and were withdrawn from the study if the
supplement consumption was > 70% of the prescribed dose.
2.4. Outcome measures
Efﬁcacy assessments included the following: glucose [FPG,
plasma glucose during OGTT (postprandial plasma glucose: PPG),
glucose incremental area under the curve (iAUC), and glucose
maximum concentration (Cmax)], insulin [fasting plasma insulin
(FPI), plasma insulin during OGTT (postprandial plasma insulin:
PPI), insulin iAUC, and insulin Cmax], homeostatic model assess-
ment (HOMA)einsulin resistance (IR), and HOMA-b, glycated al-
bumin, fructosamine, and HbA1c. The glucose and insulin iAUCs
during the OGTT were determined by the trapezoidal method.
Safety assessments included the following: electrocardiogram,
hematology, and laboratory tests (white blood cells, red blood cells,
hemoglobin, hematocrit, platelet count, total protein, albumin,
alanine aminotransferase, aspartate aminotransferase, blood urea
nitrogen, creatinine, etc.), pulse rate, and blood pressure, along
with a personal report and were recorded at every visits.
Blood samples were analyzed on a Hitachi 7600-110 analyzer
(Hitachi High-Technologies Corporation, Tokyo, Japan).
2.5. Statistical analysis
Statistical analysis was performed using SAS version 9.2 (SAS
Institute, Chicago, IL. USA). Data are shown as the mean values and
Fig. 1. CONSORT diagram showing the study ﬂow during the 8-wk intervention.
Fig. 2. Blood glucose level and incremental area under the curve (iAUC) obtained
during the oral glucose tolerance test prior to and after treatment with hydrolyzed
ginseng extract or placebo. All values are presented as mean  standard deviation.
Derived from generalized linear model adjusted for baseline and p-value compared to
the placebo group. *p < 0.05
S.-H. Park et al / Antidiabetic effects of HGE 241standard deviation. A Chi-square test was performed to determine
differences at baseline in frequencies of categorized variables be-
tween the groups. The Student paired t test was used for contin-
uous measures to assess differences between prior to and after the
8-wk intervention period. A linear mixed-effects model was
applied to repeated measures data for each continuous outcome
variable and data. Fixed effects included treatment group, treat-
ment visit, and the interaction between treatment group and visit.
A p-value < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Participants
Among the 100 participants screened, 77 participants were
excluded due to laboratory test results consistent with the exclu-
sion criteria. The remaining 23 participants fulﬁlled the study
criteria and were distributed into two groups, HGE (n¼ 12, 960mg/
day) and placebo (n ¼ 11).
One participant from the HGE group and two participants from
the placebo group withdrew from the study due to personal rea-
sons. Twenty participants (11 in HGE group and 9 in placebo group)
were able to ﬁnish the study (Fig. 1).
3.2. Participant characteristics
General characteristics of the participants are shown in Table 2.
There were no signiﬁcant differences in baseline characteristicsTable 2
Demographic characteristics of the study participants
Placebo group (n ¼ 9) HGE group (n ¼ 11) p1)
Age (y) 44.56  10.48 50.45  12.36 0.271
Weight (kg) 68.00  12.75 67.00  11.43 0.855
Height (cm) 165.33  7.89 167.18  11.33 0.684
Sex (M/F) 4/5 6/5 1.0002)
FPG (mg/dL) 105.56  6.54 109.36  6.96 0.227
FPG (mmol/L) 5.9  0.4 6.1  0.4 0.227
All values are presented as mean  standard deviation
FPG, fasting plasma glucose. HGE, hydrolyzed ginseng extract
1) Analyzed by independent t-test and p-value compared to the placebo group
2) Analyzed by Fisher’s exact testbetween the HGE and placebo groups, such as age, sex, weight,
height, and FPG.3.3. Safety evaluation
At each of the clinic visits by the study participants, the in-
vestigators determined whether there were any adverse events
experienced since the previous visit. No moderate or serious
adverse events were reported during the 8-wk study period. The
evaluation was also expanded to include laboratory tests, electro-
cardiogram, and vital signs (blood pressure and pulse). The results
of the clinical tests were in the normal range, so no participants
withdrew because of adverse events.Fig. 3. Blood insulin level and incremental area under the curve (iAUC) obtained
during the oral glucose tolerance test prior to and after treatment with hydrolyzed
ginseng extract or placebo. All values are presented as mean  standard deviation.
Derived from generalized linear model adjusted for baseline.
Table 3
Homeostatic model assessment (HOMA)einsulin resistance (IR) and HOMA-b level obtained prior to and after treatment with hydrolyzed ginseng extract (HGE) or placebo
Placebo group (n ¼ 9) HGE group (n ¼ 11) p2)
0 week 8 week p1) 0 week 8 week p1)
HOMA-IR 1.87  0.91 2.70  2.10 0.173 2.73  2.11 1.91  1.08 0.193 0.137
HOMA-b 61.16  24.45 74.68  48.41 0.316 62.60  37.15 57.18  36.01 0.638 0.282
All values are presented as mean  standard deviation
1) Analyzed by paired t-test and p-value compared to baseline visit
2) Derived from generalized linear model adjusted for baseline and p-value compared to placebo group
J Ginseng Res 2014;38:239e2432423.4. Efﬁcacy evaluation
Changes in FPG, PPG, glucose iAUC, glucose Cmax, FPI, PPI, insulin
iAUC, and insulin Cmax prior to and after the 8-wk intervention
period are shown in Figs. 2, 3. After the 8-wk intervention, statis-
tically signiﬁcant differences were found in FPG (p ¼ 0.017) and
PPG60min (p ¼ 0.01). PPG30min (p ¼ 0.059), FPI (p ¼ 0.063), and
PPI60min (p ¼ 0.077) showed a tendency to improve more than the
placebo group, although there were no signiﬁcant differences be-
tween the groups.
Changes in HOMAeIR and HOMA-b prior to and after the 8-wk
intervention period are shown in Table 3. After the 8-wk inter-
vention, there were no signiﬁcant differences between the groups.4. Discussion
The objective of this study was to determine the effect of HGE
supplementation on the glycemic control in patients with IFG in-
dividuals and consequently be a possible nutritional approach to
reducing the incidence of type 2 diabetes development. Although
ginseng has been reported to possess antidiabetic activities in type
2 diabetic animals [21,22] and patients [23,24], the effect of HGE
on type 2 diabetic patients or high-risk individuals has not been
reported. After HGE supplementation, impaired fasting glucose
levels returned to near-physiological levels after 8 wk of
supplementation.
In general, deglycosylated ginsenosides are more readily
absorbed by the human intestinal tract than their counterparts and
have greater pharmacological functions. Nevertheless, these forms
of ginsenosides are difﬁcult to obtain because of their lower natural
abundance in ginseng extract. Additionally, it is very difﬁcult to
synthesize deglycosylated ginsenosides chemically in order to
develop them into a therapeutic medicine. In this regard, various
attempts, including microbial conversion and enzymatic catalysis,
have been made to enrich ginsenosides with less sugar. In this
study, we used an enzymatic catalysis method because this
approach has substantial advantages such as high selectivity, mild
reaction conditions, and environmental compatibility. Pectinase is
an enzyme able to degrade pectic substances by hydrolyzing the
ester bond between galacturonic acid and methanol or by cleaving
the glycosidic bonds of speciﬁc polymers [22]. Indeed, Jin et al [17]
used pectinase to hydrolyze ginsenosides and found that com-
pound K is more readily absorbed from HGE compared to non-HGE
in human individuals. Compound K has received increasing atten-
tion because various pharmacologic actions including anticancer
[25], anti-inﬂammation [26], and antidiabetes [27] were shown to
be mediated by this compound. Using pectinase-hydrolyzed
ginseng extract, Ramesh et al [28] found an improved antioxidant
status and minimized occurrence of oxidative stress-related dis-
orders in aged rats. Moreover, Yuan et al [29,30] reported that
pectinase-processed ginseng radix had antidiabetic and hypolipi-
demic effects in high fat diet-fed ICR mice. Taken together, pecti-
nase seems to be an effective tool to transform ginsenosides intodeglycosylated ginsenosides, thereby enhancing the bioavailability
and functionality of ginseng.
Our data demonstrate that 8 wk of HGE supplementation causes
a signiﬁcant reduction in FPG (p¼ 0.017) and PPG60min (p¼ 0.01) in
IFG individuals. Such reductions may be due to one or a combina-
tion of different mechanisms, including intestinal glucose absorp-
tion [31,32], insulin secretion from pancreatic b-cells [33], or
peripheral glucose utilization [34]. After the supplementation of
HGE, noticeable but not signiﬁcant difference was found in the
glucose level at an earlier time point (PPG30min, p ¼ 0.059) during
OGTT. This result suggests that HGE slows the absorption of glucose
in the intestinal lumen. Also, our ﬁndings of signiﬁcant decreases in
FPG and PPG60min suggest one additional possibility, in which HGE
improves glucose intolerance through increasing the insulin action
on the target tissues responsible for glucose uptake. Moreover, FPI
(p ¼ 0.063) and PPI60min (p ¼ 0.077) showed a tendency to improve
in the HGE group compared to the placebo group. In supporting this
possibility, ginsenosides CK and Rg1 have been reported to enhance
insulin-mediated glucose uptake in 3T3-L1 adipocytes, which is
related to the increased GLUT4 translocation [27,35]. Similarly,
administration of HGE improves glucose homeostasis and insulin
resistance state (or glucose and lipid parameters) in high fat diet-
fed mice via activation of AMP-dependent protein kinase in muscle
tissue [29,30]. In this study, however, there was no signiﬁcant dif-
ference in HOMA-b, suggesting no effect on insulin secretion. In
contrast to our results, studies reveal that ginseng signiﬁcantly
stimulates insulin release from pancreatic b-cells [36,37]. These
discrepancies could be due to the differences in designs (human
studies vs. animal studies) and materials (hydrolyzed ginseng vs.
nonhydrolyzed ginseng) used in the studies. Because this was a
relatively small-scale and short-term study, further large-scale and
long-term studies are needed to fully evaluate the detailed mech-
anism of HGE.
We allowed participants tomaintain their usual diet and activity
without conducting surveys about their lifestyles. Therefore, the
participants’ diets and activity levels were not accurately
controlled. For amore accurate study, the control of lifestyle factors,
such as food intake and physical activity, is necessary. Despite this
limitation, data from our study suggest that HGE is effective as a
glucose-lowering agent. Thus, combined with lifestyle modiﬁca-
tion, the glucose-lowering effect of hydrolyzed ginseng will
become more pronounced.Conﬂicts of interest
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